0001415889-24-004473.txt : 20240220
0001415889-24-004473.hdr.sgml : 20240220
20240220184804
ACCESSION NUMBER: 0001415889-24-004473
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240215
FILED AS OF DATE: 20240220
DATE AS OF CHANGE: 20240220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dubow Adam
CENTRAL INDEX KEY: 0001744507
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40431
FILM NUMBER: 24655669
MAIL ADDRESS:
STREET 1: DAY ONE BIOPHARMACEUTICALS, INC.
STREET 2: 2000 SIERRA POINT PARKWAY, SUITE 501
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001845337
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 832415215
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY, SUITE 501
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 650 484-0899
MAIL ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY, SUITE 501
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC
DATE OF NAME CHANGE: 20210209
4
1
form4-02202024_110256.xml
X0508
4
2024-02-15
0001845337
Day One Biopharmaceuticals, Inc.
DAWN
0001744507
Dubow Adam
2000 SIERRA POINT PARKWAY, SUITE 501
BRISBANE
CA
94005
false
true
false
false
GENERAL COUNSEL
0
Common Stock
2024-02-15
4
M
0
2962
A
14390
D
Common Stock
2024-02-15
4
M
0
1750
A
16140
D
Common Stock
2024-02-15
4
M
0
3687
A
19827
D
Common Stock
2024-02-16
4
S
0
3242
15.2481
D
16585
D
Restricted Stock Unit (RSU)
2024-02-15
4
M
0
2962
0
D
Common Stock
2962
32588
D
Restricted Stock Unit (RSU)
2024-02-15
4
M
0
1750
0
D
Common Stock
1750
19250
D
Restricted Stock Unit (RSU)
2024-02-15
4
M
0
3687
0
D
Common Stock
3687
55313
D
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Charles N. York II, as Attorney-in-Fact
2024-02-20